<scp>ISPAD</scp> Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and adolescents with diabetes

Abstract

E. Cengiz is a scientific advisor for Eli Lilly, Novo Nordisk, Adocia and Arecor. TD has received speaker's honoraria and research support from or has consulted for Astra Zeneca, Bayer, Boehringer, Dexcom, Eli Lilly, Lifescan, Medtronic, Novo Nordisk, Provention Bio, Roche, Sanofi, Ypsomed and is a shareholder of Drea Med Ltd. TA, JF, DB, SH, MP, E. Codner have no disclosures.